The National Agency for Food and Drugs Administration and Control (NAFDAC) has notified the public of the recall of 45,000 units of Ryaltris (olopatadine hydrochloride and mometasone furoate) nasal spray.
The product with batch number 14230425 was manufactured by Glenmark Pharmaceutical Inc.
The agency disclosed this on Thursday via its social media handle X, formerly Twitter.
Ryaltris is an antihistamine and a corticosteroid nasal spray, used to treat symptoms of seasonal allergies in people 12 years of age and older.
NAFDAC said the product could lead to temporary or medically reversible adverse health consequences, though the probability of serious harm is remote.
The company recalled the affected lot due to defective delivery system, which is a safety concern.
NAFDAC implored importers, distributors, retailers and consumers to exercise caution and vigilance within the supply chain to avoid the importation, distribution, sale and use of the affected lots of the product.
“All medical products must be obtained from authorized/licensed suppliers.
“The products’ authenticity and physical condition should be carefully checked,” it stated.
The agency further advised that anyone in possession of the affected lots should immediately discontinue sale or use and submit stock to the nearest NAFDAC office.
It added that anyone that has used the product, knows someone that has used it, or suffered any adverse reaction after use should seek immediate medical advice from a qualified healthcare professional.
Healthcare professionals and patients were encouraged to report adverse events or side effects related to the use of the product to the nearest NAFDAC office, or through the e-reporting platforms available on the NAFDAC website www.nafdac.gov.ng or via the Med-safety mobile application or via e-mail at [email protected].
NAFDAC also urged healthcare professionals and consumers to report any case of substandard and falsified medicines to its nearest office, or via phone number at 0800- 162-3322 or via email: [email protected].